Survival of Cancer Patients in Northeast China: Analysis of Sampled Cancers from Population-Based Cancer Registries.
- Author:
Yanxia LI
1
;
Liya YU
;
Jun NA
;
Shuang LI
;
Li LIU
;
Huijuan MU
;
Xuanjuan BI
;
Xiaoxia AN
;
Xun LI
;
Wen DONG
;
Guowei PAN
Author Information
- Publication Type:Original Article
- Keywords: Neoplasms; Population-based study; Cancer registry; Survival rate; China
- MeSH: Breast Neoplasms; China*; Esophageal Neoplasms; Hong Kong; Humans; Investments; Japan; Korea; Liver Neoplasms; Lung Neoplasms; Pancreatic Neoplasms; Registries*; Survival Rate; Thyroid Neoplasms; Urinary Bladder Neoplasms
- From:Cancer Research and Treatment 2017;49(4):1106-1113
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The cancer survival was characterized by following up sampled subgroups of cancer cases from three population-based cancer registries in Northeast China. MATERIALS AND METHODS: Survival analysis was used to analyze 6,871 patients, who had one of the 21 most common cancers based on sampling from the population-based cancer registries of three cities in Liaoning Province. All patients were diagnosed between 2000 and 2002 and were followed up to the end of 2007 by active and passive methods. The 5-year age standardized relative survival rates (ASRS) were estimated for all cancers combined and each of the 21 individual cancers. RESULTS: The survival status was traced for 80.8% of 8,506 sampled cancer cases. The 5-year ASRS for all 21 cancers combined was 41.5% (95% confidence interval, 40.3 to 42.7), the highest ASRS was observed for thyroid cancer (85.2%), breast cancer (78.9%), uterine corpus cancer (75.9%), and urinary bladder cancer (70.2%); the lowest 5-year ASRS was noted in pancreatic cancer (8.8%), liver cancer (11.0%), esophageal cancer (18.8), and lung cancer (19.6%). The cancer survival rates in Liaoning cities were similar to those of urban areas in mainland China, but significantly lower than those in Hong Kong, Korea, and Japan. CONCLUSION: The strikingly poor cancer survival rates in three cities of Liaoning Province and in other places in China highlight the need for urgent investment in cancer prevention, early detection, and standardized and centralized treatment.
